PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Tauopathies

Drugs in development · updated 30 October 2026

Tauopathies: drugs in development

As of 30 October 2026 there are 9 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for tauopathies. 7 are experimental, that is not yet approved in the United States.

9Active trials
7Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
ML-007C-MAII2NCT06887192
NIO752II2NCT07868328
18F-FlorbetabenI1NCT05361382
18F-NAV-4694I1NCT05361382
LY3954068I1NCT06297590
11C-M503Early I1NCT06303921
18F-JSS20-183AEarly I1NCT06932809

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
DonanemabKisunla®III1NCT05508789
18F-AV-1451[18F] Flortaucipir, Flortaucipir F18I1NCT06297590
Vizamyl18F-Flutemetamol, flutemetamol F 18I1NCT05361382

Sorted by most advanced phase and number of active trials.

All 10 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D024801 “Tauopathies”.

ItalianoFrançaisDeutsch